BioSight
Back

AKRO

NASDAQSOUTH SAN FRANCISCO, CA
Akero Therapeutics

Akero Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapeutics for metabolic and liver diseases. The company's lead program is EFX, a small molecule in Phase 3 development being evaluated in the SYNCHRONY program for the treatment of nonalcoholic fatty liver disease. Akero is advancing product candidates through clinical trials with the goal of obtaining regulatory approval and commercializing treatments in the metabolic disease space.

$54.65+75.61%1Y
AKRO · daily close · illustrative · 0 catalysts marked
1Y high$57.561Y low$21.87range$35.69(163%)past catalysts

Pipeline1

efruxifermin (EFX)
UnknownIndication pending review

Catalyst Calendar1

Past (1)
JAN 27
2025
Readoutefruxifermin (EFX)
“On January 27, 2025, the Company released preliminary topline week 96 results from SYMMETRY, a Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin ("EFX") in patients with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh Class A, due to metabolic dysfunction-associated steatohepatitis ("MASH").”
8-K ↗

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.